trial summary · NCT07863011
Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease Dementia
A Prospective, Single-Center, Randomized, Subject-Assessor Double-Blind, Sham-Controlled, Exploratory Clinical Trial to Evaluate the Pre- and Post-Treatment Changes of HeLaXON, a Low-Dose Radiation Therapy Device, in Patients With Mild AD Dementia
Trial record from the TrialBase DB dataset, status RECRUITING, condition Alzheimer Disease, sponsored by ReadyCure Inc.. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This randomized, sham-controlled, exploratory clinical trial will evaluate the efficacy and safety of HeLaXON, an investigational low-dose radiation therapy device, in patients with mild Alzheimer's disease dementia. A total of 30 participants will be randomly assigned in a 1:1 ratio to receive either low-dose whole-brain radiation therapy or a sham procedure using the same device. Participants in the treatment group will receive 0.04 Gy per session twice weekly for 3 weeks, for a total of 6 sessions and a cumulative dose of 0.24 Gy. Participants in the sham group will undergo the same device procedures without radiation delivery. Participants and outcome assessors will remain blinded to treatment assignment. Changes in cognitive function, dementia severity, daily functioning, and amyloid burden will be evaluated at 6 and 12 months after treatment. Safety will be assessed throughout the study. Exploratory blood biomarkers, including plasma Aβ42/40 ratio, p-tau217, and Aβ oligomer, will also be evaluated.
Source record: https://clinicaltrials.gov/study/NCT07863011
Facts
| registry id | NCT07863011 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | not reported |
| study type | INTERVENTIONAL |
| lead condition | Alzheimer Disease |
| sponsor | ReadyCure Inc. |
| sponsor class | INDUSTRY |
| enrollment | 30 |
| start date | 2026-10-26 |
| primary completion | 2028-03-31 |
| completion | 2028-12-30 |
| results posted | not reported |
Conditions
- Alzheimer Disease
Interventions
- HeLaXON 1X Low-Dose Radiation Therapy
- Sham HeLaXON 1X Procedure
Countries
- South Korea
Intervention types: DEVICE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.